209 results about "Pharmacologic therapy" patented technology

The invention relates to the field of biological medicine, in particular to a carrier-free nanoparticle which is formed by self-assembly of cyclosporine A and costunolide through intermolecular weak interaction. The invention also provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating xerophthalmia. The carrier-free nano eye drops based on the synergistic effect of Chinese and western medicines are used for anti-inflammatory treatment of the xerophthalmia, a new strategy is provided for precise diagnosis and treatment of the xerophthalmia, the problems of single target spot, limited curative effect and the like in traditional treatment are solved, and more efficient inflammation control is expected to be achieved. While the curative effect is improved, the tolerance risk caused by long-term use is reduced, double optimization of the curative effect and safety is realized, and the limitation of traditional single drug treatment is broken through. By adopting the carrier-free nano preparation, the delivery efficiency of the medicine on the ocular surface is effectively improved, the bioavailability is enhanced, powerful support is provided for improving the curative effect of the medicine, and the carrier limitation bottleneck is broken through.

The invention discloses a preparation method and application of a granzyme B response near-infrared two-region ratiometric fluorescent probe (DCGA). The DCGA combines the NIR-II dual-emission fluorescence characteristic of rare earth ions with a ratio-type signal response mode, the sensitivity and signal stability of in-vivo fluorescence imaging are greatly improved, ultralow or enhanced F1060nm fluorescence signals are respectively shown before and after interaction with granzyme B (GzmB), F1525nm fluorescence signals are almost kept unchanged, and the DCGA can be used for detecting the in-vivo fluorescence imaging of the granzyme B (GzmB). Therefore, the self-calibration ratio fluorescence imaging GzmB activity change is realized. The DCGA is applied to tumor treatment of immunotherapy drugs, and responders and non-responders of immunotherapy can be distinguished in a non-invasive early stage through ratio fluorescence signals of the DCGA. Therefore, the fluorescent probe can be used as an effective GzmB active NIR-II ratio fluorescence imaging tool, and is expected to provide powerful support for immunotherapy research, precision medicine and personalized diagnosis and treatment.

Various methods and systems for efficiently providing pharmacogenetic guidelines is disclosed. A drug prescription and a patient genotype can be analyzed to provide a drug therapy recommendation. The analysis can include comparing the patient genotype and the drug name to a drug profile database, a molecular biomarker database, hospital drug reaction records and omics databases, and calculating the patient response to the drug.

The invention discloses a combined treatment medicine for acute myelogenous leukemia. The combined treatment medicine is prepared from vinaclaria, azacitidine and aclarithromycin. The medicine is applied to preparation of an acute myelogenous leukemia cell proliferation inhibitor; the medicine is applied to preparation of an acute myelogenous leukemia cell apoptosis inducer. The three medicines are combined to achieve a synergistic effect: the three medicines have a synergistic anti-tumor effect instead of a simple superposition effect, and a new combined medication mechanism is a result obtained through laboratory research and an initial effect of clinical application. The subsequent consolidation treatment scheme may also be used for part of initially treated patients with acute myelogenous leukemia, which are not suitable for enhanced chemotherapy or intense intense treatment by using targeted drugs, and relapse / refractory patients with acute myelogenous leukemia, and a better treatment scheme can also bring new hope and dawn to more patients.

The invention relates to the technical field of medicines, in particular to application of KLB protein in preparation of a medicine for treating schistosome infection. The invention verifies the treatment effect of the KLB protein on hepatic tissue EMT and fibrosis caused by schistosoma japonicum infection, and proves that the KLB can be used as a medicine for treating schistosoma japonicum hepatic fibrosis.

The invention provides application of a CHD1L detection reagent in preparation of a drug-resistant breast cancer screening kit, and belongs to the field of biological medicine. Researches find that when the CHD1L gene expression level in cancer tissues of a breast cancer patient is high, the breast cancer patient is prone to drug resistance to paclitaxel drugs, and the treatment effect of the paclitaxel drugs is poor. The reagent for detecting the CHD1L gene expression level is used for preparing the drug-resistant breast cancer screening kit, can be used for auxiliary diagnosis of clinical breast cancer types, provides an effective basis for related treatment measures or decisions of patients, and has a good clinical application prospect.

Optimized bio-synchronous drug delivery begins with establishing a bio-synchronous treatment protocol that incorporates individual temporal and innate biological characteristics into a pharmacological treatment plan. The bio-synchronous treatment protocol is thereafter initiated using bioactive agent delivery device. Bio-synchronous drug delivery includes continual collection of patient data such as physical, psychological, temporal and environmental characteristics. This data is analyzed so to not only determine an initial treatment protocol but to also determining whether modification to the ongoing bio-synchronous treatment protocol is required. And, responsive to determining a modification is required the system modifies the bio-synchronous treatment protocol and use of delivery device. These modifications and treatment protocols can include reactive and proactive psychological support supplied to the patient in a variety of formats.

The invention discloses application of selazinomethyl ether and a pharmaceutical composition thereof in preparation of a medicine for preventing or treating brain injury. The invention provides the application of selazine methyl ether in preparing the medicine for preventing or treating the brain injury for the first time, and selazine methyl ether has a remarkable effect in preventing or treating the brain injury, especially cerebral arterial thrombosis and the brain injury caused by hemorrhagic transformation of the cerebral arterial thrombosis. And cerebral injury caused by cerebral arterial thrombosis and hemorrhagic transformation can be obviously relieved. According to the application disclosed by the invention, the sefoazinomethyl ether has the effects of remarkably reducing the cerebral infarction area and behavioral scoring under the condition of middle cerebral artery occlusion; the selobezine methyl ether has the effects of remarkably reducing the hemorrhage area, hemorrhage score and behavioral score under acute high glucose and middle cerebral artery occlusion; the pharmaceutical composition containing selazine methyl ether can become a novel drug for preventing or treating brain injury, and can be used for treating various cerebrovascular diseases including cerebral arterial thrombosis and hemorrhagic transformation of cerebral arterial thrombosis.

A method for treating inflammatory bowel disease using prolyl hydroxylase domain-containing protein (PHD) inhibitors and additional agents is described herein.

The invention provides an application of a human C1orf186 gene or a human C1orf186 protein in preparation of a targeted therapeutic drug for ovarian cancer, and relates to the technical field of biomedical engineering. The invention relates to an application of a human C1orf186 gene or a human C1orf186 protein in preparation of an ovarian cancer targeted therapy drug. Experiments prove that C1orf186 is an ovarian cancer cell surface specific membrane protein molecule, a C1orf186 positive cell population has tumor stem cell characteristics, and prepared human C1orf186 lentivirus packaging plasmids and other targeted therapeutic drugs have an obvious inhibition effect on the growth of ovarian cancer. Therefore, the invention provides a specific target C1orf186 for molecular therapy of the ovarian cancer, also provides several targeted drug types, and more importantly provides a thought for treating the ovarian cancer by using the anti-C1orf186 targeted drug, thereby laying a foundation for deeply researching the function of the C1orf186. Meanwhile, the invention provides reliable theoretical basis and experimental data for clinical treatment of ovarian cancer, and has important significance and wide prospects.

The invention provides an abnormal glycolipid metabolism risk dynamic assessment system based on SNP and gene analysis and application of the system in neuropsychiatric drug therapy, and belongs to the technical field of biological medicine. The system disclosed by the invention contains the primer probe group for detecting the metabolic influence of the antipsychotic drug, so that specific amplification detection of a specific SNP site can be realized, clinical guidance is targeted, and abnormal glucose and lipid metabolism and significant change of body weight are avoided. According to the method, glucose and lipid metabolism and effect target gene detection products are adopted for detection, a detection result is evaluated and interpreted through a glucose and lipid metabolism abnormal risk dynamic evaluation algorithm, retrospective investigation and actual case observation are combined, the detection result is good in sensitivity, high in accuracy and high in practicability, sampling is convenient, the evaluation algorithm is professional and reasonable, and the method is suitable for popularization and application. Results are easy to understand and easy to popularize and use.

A technique is provided for identifying correct or sufficient doses in a patient being treated with a drug for a neurological deviation condition. A method may include performing a plurality of fright response tests on a user, each test utilizing a device having a camera, a display, and optionally a speaker, and each test occurring at a different time after the user has been administered a medicament. The method may include receiving a plurality of images of at least one eye of the user from a camera during each test, and then calculating a magnitude of eyelid closure based on each image. The method may include determining a value of a correlation between a predetermined plasma concentration of the drug and the determined amplitude, and then determining whether a correct or sufficient dose has been reached based on the value of the correlation.

The invention discloses an STING agonist polypeptide conjugate as well as a composition and application thereof, and belongs to the field of medicinal chemistry, an STING agonist and a straight-chain peptide or a cyclic peptide are directly connected or connected through a linking group, the formed conjugate can target a tumor microenvironment, and the STING agonist is controllably released in specific time and space, so that the tumor microenvironment is inhibited, and the tumor microenvironment is inhibited. Therefore, the drug enrichment amount of the tumor site is increased, the drug treatment efficiency and bioavailability are improved, the toxic and side effects are reduced, and the purposes of effect enhancement and toxicity reduction are achieved. According to the STING agonist polypeptide conjugate, the targeting property of STING agonist drugs on tumor tissues is improved, the toxic and side effects on normal tissues are reduced, the STING agonist polypeptide conjugate is a brand-new immune agonist type coupling drug, and a new scheme is provided for tumor immunotherapy research.

In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and / or an anti-IL-12 / 23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and / or and a sphingosine-1-phosphate receptor agonist agent.

The invention relates to the technical field of physiological monitoring, in particular to a hepatocellular carcinoma treatment effect analysis system and method based on metabolism comprehensive analysis, and the method comprises the steps: obtaining the evolution condition of hepatocellular carcinoma, the composition condition of drugs and the composition condition of metabolites; drug absorption and transformation analysis is carried out based on the composition condition of the drug and the marking condition of the composition condition of the metabolite, future drug transformation component prediction is carried out based on the drug absorption and transformation analysis result and the evolution condition of the corresponding hepatocellular carcinoma, and drug treatment effect early warning is carried out based on the future drug transformation component prediction. The first-pass effect is corrected through mass spectrum imaging and enzyme activity, the inhibition effect of the tumor microenvironment on drug transformation is quantified, prediction is dynamically adjusted through the future tumor anomaly score ratio, and the accuracy of the time of drug replacement is improved.

The invention provides a traditional Chinese medicine composition for treating Alzheimer's disease. Relates to the technical field of traditional Chinese medicine preparations, the weight part ratio of rhizoma polygonati to radix astragali is 1: (1-1.2), a progressive increase type structure is adopted among rhizoma polygonati, radix astragali and poria cocos, and the progressive increase type structure meets the condition that radix astragali is larger than or equal to poria cocos and is larger than or equal to rhizoma polygonati; the sum of the parts by weight of the basic support components accounts for 40-55% of the total parts by weight of the traditional Chinese medicine composition. According to the traditional Chinese medicine composition for treating the Alzheimer's disease, the basic support component, the collateral dredging and regulating component and the active intervention component are reasonably distributed through a definite fixed matching structure, and it is ensured that all the components cooperate with one another and act more stably. By setting an incremental structure and a bidirectional locking proportional structure between the medicinal materials, the composition fluctuation is reduced, so that the composition of each batch has higher consistency, and the stability of the treatment effect of the medicine is enhanced.

The application provides a method for constructing a spontaneous esophageal precancerous lesion or esophageal cancer non-human animal model and application thereof. The non-human animal model of spontaneous esophageal precancerous lesion or esophageal cancer is obtained by deleting the expression of Trp53 and Cdkn2a in the non-human animal. The non-human animal model prepared by the application can be used as an ideal animal model for screening drug candidates, evaluating the therapeutic effect of drugs, evaluating the toxicological effect of drugs and researching the pathogenesis of esophageal precancerous lesion or esophageal cancer.

The invention discloses a preparation method and application of tanshinone IIA and cryptotanshinone amide derivatives. The tanshinone IIA and cryptotanshinone amide derivatives are compounds shown in a general formula (I) or stereoisomers, racemes, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, pharmaceutically acceptable salts or prodrugs of the compounds. The tanshinone IIA and cryptotanshinone amide derivative can be used for preparing anti-inflammatory drugs, antibacterial drugs, tumor drugs, drugs for treating cardiovascular and cerebrovascular diseases, drugs for treating burns and scalds and drugs for treating infectious diseases.

The present invention relates to novel molecules that can be employed for the prevention, alleviation, treatment and / or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (PDD)) or Diffuse Lewy Body Disease. The invention relates to alpha-synuclein binding molecules, in particular to alpha-synuclein antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present molecules can also be used for determining a predisposition to such a disorder, disease or abnormality, monitoring residual disorder, disease or abnormality, or predicting the responsiveness of a patient who is suffering from such a disorder, disease or abnormality to treatment with a certain medicament.

The invention belongs to the field of biological medicine, and particularly relates to a YBX3 gene, a YBX3 gene inhibitor and application of the YBX3 gene inhibitor. The invention discloses application of the YBX3 gene as a biomarker in preparation of a product for detecting cardiac fibrosis. The nucleotide sequence of the YBX3 gene is as shown in SEQ ID NO. 1. The invention discloses application of a YBX3 gene inhibitor in preparation of drugs for preventing and / or treating heart diseases. The YBX3 gene inhibitor is shRNA (short hairpin ribonucleic acid) and has a nucleotide sequence as shown in SEQ ID NO. 3. When myocardial infarction occurs, mRNA and protein level expression activity of the YBX3 gene is remarkably improved and is related to fibroblast activation, and the silent YBX3 gene can remarkably inhibit fibroblast activation. The existing myocardial infarction injury medicine has a limited treatment effect, so that the YBX3 can improve the clinical prognosis of myocardial infarction injury by regulating and controlling the activation of cell fibrosis.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

The invention relates to medicine and can be used for overcoming stuttering by developing the rhythmic component of speech. Exercises are performed on a step-by-step basis. In a first step, exercises are performed for the muscles of the respiratory, phonatory and articulatory systems. In a second step, an individual non-speech rhythm is cultivated. In a third step, a sense of rhythm is developed. In a fourth step, a poetic speech rhythm is cultivated. In a fifth step, a prosaic speech rhythm is cultivated. In a sixth step, narrative and interrogative intonations are cultivated. In a seventh step, rhythmic processes are trained to become automatic in independent speech. The method makes it possible to overcome psychogenic and neurogenic stuttering, without the use of medication or the risk of relapse, and is suitable for all age groups.

To provide a prediction method and device for drug effect of a compound that can predict drug effect on all molecules present in the living world, and further can predict drug effect on a disease for which there is no existing drug available.SOLUTION: There is provided a prediction method for drug effect of a compound, which includes: a process S2 of creating a first coupling affinity profile as a coupling affinity profile of a prediction object compound group and an in vivo protein group; and a process S5 of predicting drug effect of the prediction object compound group based upon the created first coupling affinity profile and a second coupling affinity profile as a coupling affinity profile of a compound group whose drug effect information is present and the in vivo protein group.SELECTED DRAWING: Figure 1

The application provides a method for constructing an animal model of systemic lupus erythematosus, and the animal model of systemic lupus erythematosus shows high autoantibody, low complement, high inflammatory factor and severe kidney damage. The animal model of systemic lupus erythematosus provided by the application has a clear cause, can cause abnormalities of innate immunity and acquired immunity systems, and has a short experimental cycle, thereby providing a new animal model for drug candidate screening, drug treatment effect evaluation and pathogenesis research of systemic lupus erythematosus.

This invention relates to the field of bioinformatics, and particularly to an artificial intelligence-based drug relocation method, apparatus, device, and storage medium. The AI-based drug relocation method of this invention first constructs a heterogeneous network, and then builds a relocation model including a multi-relational heterogeneous graph encoder, a multi-head attention mechanism module, and an interactive decoder. Based on the heterogeneous network, it predicts the treatment score of a drug for a disease, achieving better test metrics compared to other methods. Furthermore, this invention interprets the prediction results, identifying key functional nodes and explaining the pharmacological mechanism of drug treatment for diseases.

Relates to an anti-IL4R antibody. Specifically, the invention provides an antibody capable of specifically binding to IL4R or an antigen binding fragment thereof, and the antibody or the antigen binding fragment thereof can specifically bind to IL4R with high affinity and can be used as a drug for treating IL4R-related diseases.

The invention relates to the technical field of biological medicine, in particular to a multifunctional ternary complex based on cyclodextrin and a preparation method thereof. The invention provides a multifunctional curcumin / methotrexate ternary complex based on beta-cyclodextrin. The ternary complex can realize synergistic delivery and controlled-release release of natural polyphenol and synthetic drugs in a medication mode of'one dose with multiple effects'. Meanwhile, the problems that a traditional medicine is poor in water solubility and low in bioavailability, the treatment effect of a single medicine is limited, and an existing nano delivery system is complex in structure, tedious in preparation and the like are solved, and the technical requirements of modern medicine preparations are met.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

The present invention refers to an oral pharmaceutical composition comprising minoxidil having controlled particle size for the treatment of androgenetic alopecia, as well as a medicament, methods for treatment and associated uses.